ArticleArthritis research & therapy2018
Interferon-λ3/4 genetic variants and interferon-λ3 serum levels are biomarkers of lupus nephritis and disease activity in Taiwanese.
Article in Arthritis research & therapy, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 43 citations in OpenAlex.
- Article
- Serum interferon-λ3 as a short-term biomarker of disease control in anti-MDA5-positive dermatomyositis-associated ILD.Scientific reports · 2026Article
- Interferon levels and interferon-stimulated gene expression identify patient subsets with distinct clinical and immunological characteristics in systemic lupus erythematosus.Frontiers in immunology · 2026Article
- Identification of genetic variants associated with lupus nephritis in a Taiwanese cohort through systematic genetic screening.Scientific reports · 2025Article
- Interferon Lambda: The Next Frontier in Antiviral Therapy?Pharmaceuticals (Basel, Switzerland) · 2025Review
- Soluble Herpes Virus Entry Mediator and Type II/III Interferons Are Upregulated in Primary Biliary Cholangitis.International journal of molecular sciences · 2025Article
- Uncoupling interferons and the interferon signature explains clinical and transcriptional subsets in SLE.Cell reports. Medicine · 2024Article
- Association between endothelin-1 and systemic lupus erythematosus: insights from a case-control study.Scientific reports · 2023Article
- Uncoupling interferons and the interferon signature explain clinical and transcriptional subsets in SLE.medRxiv : the preprint server for health sciences · 2023Article
- Review
- Genetic variants of interferon lambda-related genes and chronic kidney disease susceptibility in the Korean population.Kidney research and clinical practice · 2022Article
- Association of Immune-Related Genetic and Epigenetic Alterations with Lupus Nephritis.Kidney diseases (Basel, Switzerland) · 2022Review
- B Cell Activation and Plasma Cell Differentiation Are Promoted by IFN-λ in Systemic Lupus Erythematosus.Journal of immunology (Baltimore, Md. : 1950) · 2021Article
- Interferon Lambda Regulates Cellular and Humoral Immunity in Pristane-Induced Lupus.International journal of molecular sciences · 2021Article
- Cytokines as Biomarkers in Systemic Lupus Erythematosus: Value for Diagnosis and Drug Therapy.International journal of molecular sciences · 2021Review
- Regulation of B Cell Responses in SLE by Three Classes of Interferons.International journal of molecular sciences · 2021Review
- Monocytes differentiated into macrophages and dendritic cells in the presence of human IFN-λ3 or IFN-λ4 show distinct phenotypes.Journal of leukocyte biology · 2021Article
- Interferon lambda in inflammation and autoimmune rheumatic diseases.Nature reviews. Rheumatology · 2021Review
- Type III Interferons: Emerging Roles in Autoimmunity.Frontiers in immunology · 2021Review
- Interferon Lambda 3/4 (IFNλ3/4) rs12979860 Polymorphisms Is Not Associated With Susceptibility to Systemic Lupus Erythematosus, Although It Regulates OASL Expression in Patients With SLE.Frontiers in genetics · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 4 institutions in 2 countries.
Funding
Abstract
backgroundType III interferons (IFNs) or IFN-λs are the newly discovered cytokines that primarily target the cells of epithelial and myeloid lineages, which are major components of kidneys. The current study aimed to investigate whether IFN-λs are involved in the pathogenesis of systemic lupus erythematosus (SLE) and lupus nephritis.
methodsTaqMan allele discrimination assays were used to determine IFNL3/4 SNP genotypes of 1620 healthy controls and 1013 SLE patients (two independent cohorts consisting of 831 and 182 subjects, respectively) from Taiwan. The distributions of IFNL3/4 SNP genotypes and allele frequencies were compared between SLE patients and healthy controls and among SLE patients stratified by clinical phenotypes. ELISA was used to determine the serum IFN-λ3 concentrations of SLE patients.
resultsAll major IFN3/4 SNP alleles were significantly associated with the risk for lupus nephritis (rs8099917T, P
conclusionsIFN-λ3/4 genetic variants play a unique role in the development of lupus nephritis and SLE.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.